Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.
Profitability
This table compares Eloxx Pharmaceuticals and Artiva Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
| Artiva Biotherapeutics | N/A | -45.32% | -41.38% |
Institutional and Insider Ownership
2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Eloxx Pharmaceuticals and Artiva Biotherapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eloxx Pharmaceuticals | $6.36 million | 6.69 | -$5.99 million | ($1.54) | -6.76 |
| Artiva Biotherapeutics | $250,000.00 | 745.40 | -$83.86 million | ($2.98) | -1.27 |
Eloxx Pharmaceuticals has higher revenue and earnings than Artiva Biotherapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and target prices for Eloxx Pharmaceuticals and Artiva Biotherapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eloxx Pharmaceuticals | 1 | 1 | 3 | 2 | 2.86 |
| Artiva Biotherapeutics | 1 | 4 | 2 | 0 | 2.14 |
Eloxx Pharmaceuticals presently has a consensus target price of $37.33, suggesting a potential upside of 258.63%. Artiva Biotherapeutics has a consensus target price of $24.80, suggesting a potential upside of 557.82%. Given Artiva Biotherapeutics’ higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Eloxx Pharmaceuticals.
Risk & Volatility
Eloxx Pharmaceuticals has a beta of -1918.69, indicating that its stock price is 191,969% less volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500.
Summary
Eloxx Pharmaceuticals beats Artiva Biotherapeutics on 10 of the 13 factors compared between the two stocks.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on compounds intended to help cells produce functional proteins when a genetic mutation prematurely stops protein production. The company’s lead investigational candidate, ELX-02, was designed to promote ribosomal readthrough of these premature stop signals. Eloxx studied the candidate for conditions including cystic fibrosis and nephropathic cystinosis in patients with relevant genetic mutations.
About Artiva Biotherapeutics
Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company’s lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
